Both compounds block integral viral mechanisms for SARS-CoV-2 replication and infection SGX-listed Singapore eDevelopment Ltd (SeD; SGX:40V) has announced that its wholly-owned U.S. biomedical subsidiary Impact BioMedical, Inc. has through…
SGX-listed Singapore eDevelopment Limited (“SeD”, SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. (“Global BioLife”) will be presenting its research on its Functional Fragrance…
SGX-listed Singapore eDevelopment Ltd (“SeD”, SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global…
SINGAPORE – (ACN Newswire) – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”), through its subsidiary, Global BioLife Inc. (“Global BioLife”) is pleased to announce that research of their…
SINGAPORE – (ACN Newswire) – Singapore Exchange-listed Singapore eDevelopment Limited (“SeD”) announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. (“Global BioLife”), has developed a low glycemic index, naturally…
SINGAPORE — Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne…
SINGAPORE — The Board of Directors of Singapore eDevelopment Ltd (SeD) announced that its Global Systematic Multi-Strategy Fund (GSMS Fund) managed by Hengfai Asset Management Pte Ltd (HFAM), a wholly…
